Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$33.62 USD
-0.60 (-1.75%)
Updated May 30, 2024 04:00 PM ET
After-Market: $33.61 -0.01 (-0.03%) 7:22 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 141 - 160 ( 411 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Kolltan Acquisition Adds Nearer Term Catalysts, but Pipeline Still Early, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Building Toward 2017 Data Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J